Laekna, Inc. (2105.HK)
| Previous close | 7.440 |
| Open | 7.590 |
| Bid | 7.360 x N/A |
| Ask | 7.380 x N/A |
| Day's range | 7.150 - 8.000 |
| 52-week range | 3.150 - 26.450 |
| Volume | |
| Avg. volume | 6,282,064 |
| Market cap | 2.871B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.810 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireLaekna Releases 2023 ESG Report
Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, released its 2023 Environmental, Social and Governance (ESG) report since its listing on the HKEX on June 29, 2023.
PR NewswireLaekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024
Laekna (2105.HK) announced that the company has presented two internally-discovered preclinical candidates, in addition to a poster presentation on a clinical trial, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California. The presentations featured preclinical data of two novel selective inhibitors, LAE119, a novel PARP1 selective inhibitor and trapper, and LAE120, a novel selective USP1 inhibitor.
PR NewswireLaekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024
Laekna (2105.HK), a clinical-stage biotechnology company, today announced that the company will present a novel therapeutical approach to treat liver fibrosis in the form of a poster at the NASH-TAG conference from January 4-6, 2024, in Park City, Utah. The presentation will showcase a novel antibody-based aHSC depletion discovery platform and introduce preclinical anti-fibrosis data of a bi-functional NK-aHSC engager candidates derived from this platform.
